Deutsche Bank Appointed as Depositary Bank for the Sponsored American Depositary Receipt Program of Radiopharm Theranostics Limited

Rhea-AI Summary

Deutsche Bank has been appointed as the depositary bank for the American Depositary Receipt (ADR) program of Radiopharm Theranostics (OTC: RADTY). Radiopharm is a clinical stage radiotherapeutics company developing innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The company has been listed on ASX (RAD) since November 2021 and has a pipeline of distinct platform technologies spanning peptides, small molecules, and monoclonal antibodies for use in cancer treatment.

The ADR program details include:

• Country: Australia
• Custodian Bank: BNP Paribas S.A.
• Effective Date: September 18, 2024
• Level I ADR
• Symbol: RADTY
• Exchange: OTC
• Current Ratio: 1 ADS : 200 ordinary shares

Positive

• Deutsche Bank's appointment as depositary bank for Radiopharm's ADR program may increase visibility and accessibility for US investors
• Radiopharm's diverse pipeline of radiopharmaceutical products targets high unmet medical needs in cancer treatment
• The company's technologies have potential to be first-to-market or best-in-class in their respective areas

Negative

• Radiopharm is still in the clinical stage, indicating potential risks and uncertainties in product development
• As a Level I ADR program, the company's shares are traded over-the-counter, which may limit liquidity and investor access compared to major exchanges

NEW YORK--(BUSINESS WIRE)-- Deutsche Bank announced today its appointment as depositary bank for the American Depositary Receipt program of Radiopharm Theranostics Limited.

Radiopharm Theranostics Limited (OTC: RADTY) is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm has been listed on ASX (RAD) since November 2021. The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the world’s leading universities and institutes. The pipeline has been built based on the potential to be first-to-market or best in class.*

In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche Bank provides corporates, financial institutions, hedge funds and supranational agencies around the world with trustee, agency, escrow and related services. Deutsche Bank offers a very broad range of services for diverse products, from complex securitizations and project finance to syndicated loans, debt exchanges and restructurings.

* This information was provided by Radiopharm Theranostics Limited (August 2024).

Depositary Receipt Information
Country	Australia
Custodian Bank	BNP Paribas S.A. ARBN 000 000 117
Effective Date	September 18, 2024
Level I ADR
CUSIP	75041J 101
ISIN	US75041J1016
Symbol	RADTY
Exchange	OTC
Current Ratio	1 ADS: 200 ordinary shares
Eligibility	DTC

Depositary Receipt Contacts
New Business Development	Markets Distribution
Nicole Pfundstein	London
Tel: +61 2 8258 1019	Tel: +44 (0) 20 7547 6500
	New York
	Tel: +1 212 250 9100
www.adr.db.com
adr@db.com
gtb.db.com

Deutsche Bank provides commercial and investment banking, retail banking, transaction banking and asset and wealth management products and services to corporations, governments, institutional investors, small and medium-sized businesses, and private individuals. Deutsche Bank is Germany’s leading bank, with a strong position in Europe and a significant presence in the Americas and Asia Pacific.

The Depositary Receipts have been registered pursuant to the US Securities Act of 1933 (the "Act"). The investment or investment service which is the subject of this notice is not available to retail clients as defined by the UK Financial Conduct Authority. This notice has been approved and/or communicated by Deutsche Bank AG New York. The services described in this notice are provided by Deutsche Bank Trust Company Americas (Deutsche Bank) or by its subsidiaries and/or affiliates in accordance with appropriate local registration and regulation. Deutsche Bank is providing the attached notice strictly for information purposes and makes no claims or statement, nor does it warrant or in any way represent, as to the accuracy or completeness of the details contained herein or therein. This announcement appears as a matter of record only. Neither this announcement nor the information contained herein constitutes an offer or solicitation by Deutsche Bank or any other issuer or entity for the purchase or sale of any securities nor does it constitute a solicitation to any person in any jurisdiction where solicitation would be unlawful. No part of this notice may be copied or reproduced in any way without the prior written consent of Deutsche Bank. Past results are not an indication of future performance. Copyright© September 2024 Deutsche Bank AG. All rights reserved.

Issued by press department of Deutsche Bank AG NY	Internet: http://www.db.com
1 Columbus Circle, New York, NY 10019	http://www.db.com/press
Phone +1 212 250 7171	E-Mail: press-media-relations.americas@db.com

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240919086729/en/

For further information, please contact:

Deutsche Bank AG

Press & Media Relations

Dylan Riddle

Tel. +12122504982

Cell. +1(904)3866481

Email dylan.riddle@db.com

Source: Deutsche Bank

FAQ

What is the ticker symbol for Radiopharm Theranostics' ADR on the OTC market?

The ticker symbol for Radiopharm Theranostics' ADR on the OTC market is RADTY.

When did Deutsche Bank become the depositary bank for Radiopharm Theranostics' ADR program?

Deutsche Bank was appointed as the depositary bank for Radiopharm Theranostics' ADR program effective September 18, 2024.

What is the ADR ratio for Radiopharm Theranostics (RADTY)?

The current ratio for Radiopharm Theranostics' ADR (RADTY) is 1 ADS to 200 ordinary shares.

What type of company is Radiopharm Theranostics (RADTY)?

Radiopharm Theranostics (RADTY) is a clinical stage radiotherapeutics company developing innovative radiopharmaceutical products for diagnostic and therapeutic applications in cancer treatment.